

## Article

# Incidence of Air Leaks in Critically Ill Patients with Acute Hypoxemic Respiratory Failure Due to COVID-19

Robin L. Goossen <sup>1,\*†</sup>, Mariëlle Verboom <sup>1,†</sup>, Mariëlle Blacha <sup>1</sup>, Illaa Smesseim <sup>2</sup>, Ludo F. M. Beenen <sup>3</sup>, David M. P. van Meenen <sup>1,4</sup>, Frederique Paulus <sup>1,5</sup> and Marcus J. Schultz <sup>1,6,7,\*</sup>  
and on behalf of the PRoVENT-COVID and PRoAcT-COVID Investigators <sup>‡</sup>

<sup>1</sup> Department of Intensive Care, Amsterdam University Medical Centers, Location ‘AMC’, 1105 AZ Amsterdam, The Netherlands

<sup>2</sup> Department of Thoracic Oncology, Antoni van Leeuwenhoek Ziekenhuis, 1066 CX Amsterdam, The Netherlands

<sup>3</sup> Department of Radiology, Amsterdam University Medical Centers, Location ‘AMC’, 1105 AZ Amsterdam, The Netherlands

<sup>4</sup> Department of Anesthesiology, Amsterdam University Medical Centers, Location ‘AMC’, 1105 AZ Amsterdam, The Netherlands

<sup>5</sup> ACHIEVE, Centre of Applied Research, Faculty of Health, Amsterdam University of Applied Sciences, 1091 GC Amsterdam, The Netherlands

<sup>6</sup> Mahidol–Oxford Tropical Medicine Research Unit (MORU), Mahidol University, Bangkok 10400, Thailand

<sup>7</sup> Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK

\* Correspondence: r.l.goossen@amsterdamumc.nl (R.L.G.); marcus.j.schultz@gmail.com (M.J.S.)

† These authors contributed equally to this work.

‡ A full list of the collaborative investigators is provided Acknowledgments.

## Supplementary

**Table S1.** Amount of missing data in Table 1.

	<b>Patients with air leak (N = 13)</b>	<b>Patients without air leak (N = 143)</b>
Age, years	0 (0.0)	0 (0.0)
Sex, male	0 (0.0)	0 (0.0)
BMI, kg/m <sup>2</sup>	2 (15)	24 (16.8)
SOFA score	4 (30.8)	32 (22.4)
Medical History		
COPD	0 (0.0)	0 (0.0)
asthma	0 (0.0)	0 (0.0)
lung emphysema	0 (0.0)	0 (0.0)
interstitial lung disease	0 (0.0)	0 (0.0)
active smoker	7 (53.8)	66 (46.2)
history of smoking	8 (61.5)	69 (48.3)
previous pneumothorax	0 (0.0)	0 (0.0)
Home medication		
Ace inhibitors	1 (7.7)	28 (19.6)
Angiotensin receptor blocker	1 (7.7)	28 (19.6)
Ventilatory Support		
with invasive ventilation	0 (0.0)	0 (0.0)
FiO <sub>2</sub> , %	0 (0.0)	3 (2.1)
V <sub>T</sub> mL/kg PBW	2 (15.4)	41 (28.7)
PEEP, cm H <sub>2</sub> O	0 (0.0)	15 (10.5)
Pmax, cm H <sub>2</sub> O	0 (0.0)	15 (10.5)


	Patients with air leak (N = 13)	Patients without air leak (N = 143)
C <sub>RS</sub> , mL/cmH <sub>2</sub> O	5 (38.5)	52 (36.4)
with high flow nasal oxygen	0 (0.0)	0 (0.0)
FiO <sub>2</sub> , %	N.A.	0 (0.0)
flow, L O <sub>2</sub> /min	N.A.	0 (0.0)
Horowitz index		
PaO <sub>2</sub> /FiO <sub>2</sub>	0 (0.0)	2 (1.4)
PaO <sub>2</sub> /FiO <sub>2</sub> > 300 mmHg	N.A.	N.A.
PaO <sub>2</sub> /FiO <sub>2</sub> 200–300 mmHg	N.A.	N.A.
PaO <sub>2</sub> /FiO <sub>2</sub> 100–200 mmHg	N.A.	N.A.
PaO <sub>2</sub> /FiO <sub>2</sub> < 100mmHg	N.A.	N.A.

Data are N (%)

**Table S2.** Amount of missing data in Table 3.

	Patients with air leak (N = 13)	Patients without air leak (N = 143)
Duration of respiratory support, days	0 (0.0)	0 (0.0)
ICU length of stay, days	0 (0.0)	0 (0.0)
ICU mortality	0 (0.0)	0 (0.0)
28-day mortality	0 (0.0)	0 (0.0)
90-day mortality		

Data are N (%)



**Figure S1. Liberation of ventilation and ICU discharge.**

Cumulative incidence of liberation of respiratory support (left panel) and ICU discharge (right panel) with death as a competing risk, in patients with and without an air leak.